# Ellipses Pharma

Source: https://onco.cc/companies/ellipses-pharma/  
OnCo record `ellipses-pharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Ellipses Pharma is a United Kingdom-based biotechnology company running 3 late-stage cancer trials of EP0031, EP0042 and Azacitidine (AZA) in non-small-cell lung cancer, acute myeloid leukaemia and myelodysplastic syndromes / neoplasms.

## Summary

Ellipses Pharma, based in London, the United Kingdom, is a biotechnology company. Ellipses Pharma is a London-based drug development company that advances a portfolio of in-licensed oncology drug candidates through clinical trials. On ClinicalTrials.gov it is the lead sponsor of 3 recruiting or active phase 2 and phase 3 interventional cancer trials, testing EP0031, EP0042, Azacitidine (AZA) and EP0062 in non-small-cell lung cancer, acute myeloid leukaemia, myelodysplastic syndromes / neoplasms and HR-positive / HER2-negative breast cancer. The largest, NCT05443126 (A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies), plans to enrol 265 participants. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Tags: ctgov-sponsor
- HQ: London
- Type: biotech
- Website: https://www.ellipses.life

## Sources

- Official website: https://www.ellipses.life
- ClinicalTrials.gov: trials led by Ellipses Pharma: https://clinicaltrials.gov/search?lead=Ellipses%20Pharma

## Connected records

- cancers: [Acute myeloid leukaemia](https://onco.cc/cancers/aml/), [HR-positive / HER2-negative breast cancer](https://onco.cc/cancers/breast-hr-positive/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/)
- drugs: [EP0031](https://onco.cc/drugs/ep0031/), [EP0062](https://onco.cc/drugs/ep0062/)
- trials: [A Study of EP0031 (Lunbotinib) in Patients With Advanced RET-altered Malignancies](https://onco.cc/trials/nct05443126/), [Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer](https://onco.cc/trials/nct05573126/), [Study to Evaluate the Safety and Tolerability of EP0042](https://onco.cc/trials/nct04581512/)

---
JSON: https://onco.cc/api/v1/entities/ellipses-pharma.json